Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced the publication of peer-reviewed Phase 1 data for TNX-1500, its investigational anti-CD40L monoclonal antibody, in the Journal of Clinical Immunology. The study highlighted favorable safety, tolerability and pharmacodynamic results in healthy volunteers, supporting the advancement of the drug candidate into Phase 2 clinical trials.
The Phase 1 study found that TNX-1500 was generally well tolerated, with no serious adverse events reported. It demonstrated sustained suppression of T cell-dependent antibody responses and showed a half-life that supports monthly intravenous dosing. These findings pave the way for a planned Phase 2 investigator-initiated kidney transplant rejection study, expected to begin in the second half of 2026, pending FDA clearance.
TNX-1500 is a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection. The positive Phase 1 data mark a significant milestone for Tonix's immunology pipeline, which also includes TNX-4800 for Lyme disease prophylaxis. Tonix is a fully-integrated, commercial-stage biotechnology company focusing on central nervous system (CNS) and immunology treatments in areas of high unmet medical need.
The company's flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved as the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra. The company is also evaluating TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder, and its CNS portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome.
According to the press release, the full study results can be accessed at https://ibn.fm/DHiKX. Investors can find the latest news and updates regarding TNXP in the company's newsroom at https://ibn.fm/TNXP.
The publication of this data is important because it provides evidence that TNX-1500 could offer a new treatment option for kidney transplant rejection, a condition with significant unmet need. If successful in Phase 2, TNX-1500 could improve outcomes for transplant patients by potentially reducing the risk of rejection with a favorable safety profile.
